

UC Irvine

UC Irvine Previously Published Works

Title

CD46 Genetic Variability and HIV-1 Infection Susceptibility

Permalink

<https://escholarship.org/uc/item/2d7226xs>

Journal

Cells, 10(11)

ISSN

2073-4409

Authors

Serrano-Rísquez, Carmen

Omar, Mohamed

Gómez-Vidal, María Amparo

et al.

Publication Date

2021

DOI

10.3390/cells10113094

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Article

CD46 Genetic Variability and HIV-1 Infection Susceptibility

Carmen Serrano-Rísquez ¹, Mohamed Omar ², María Amparo Gómez-Vidal ², Luis Miguel Real ³ , Juan Antonio Pineda ³ , Antonio Rivero ⁴ , Antonio Rivero-Juárez ⁴, Donald Forthal ⁵, Francisco J. Márquez ¹ , Sergio Lo Caputo ⁶ , Mario Clerici ^{7,8} , Mara Biasin ⁹  and Antonio Caruz ^{1,*} 

- ¹ Unidad de Inmunogenética, Genética, Departamento de Biología Experimental, Universidad de Jaén, 23071 Jaén, Spain; csr00041@red.ujaen.es (C.S.-R.); jmarquez@ujaen.es (F.J.M.)
- ² Servicio de Enfermedades Infecciosas y Microbiología Clínica, Complejo Hospitalario de Jaén, 23007 Jaén, Spain; omarampa@gmail.com (M.O.); ampagovi@gmail.com (M.A.G.-V.)
- ³ Servicio de Enfermedades Infecciosas y Microbiología Clínica, Hospital Universitario de Valme, 41014 Sevilla, Spain; lmreal67b@gmail.com (L.M.R.); japineda@us.es (J.A.P.)
- ⁴ Instituto Maimónides de Investigación Biomédica de Córdoba (IMBIC), Hospital Universitario Reina Sofía, 14004 Córdoba, Spain; ariveror@gmail.com (A.R.); arjvet@gmail.com (A.R.-J.)
- ⁵ Division of Infectious Diseases, Department of Medicine, University of California, Irvine School of Medicine, Irvine, CA 92697, USA; dnfortha@hs.uci.edu
- ⁶ Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; sergio.locaputo@unifg.it
- ⁷ Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, University of Milan, 20122 Milan, Italy; mario.clerici@unimi.it
- ⁸ Don C. Gnocchi Foundation, IRCCS, 20148 Milan, Italy
- ⁹ Dipartimento di Scienze Biomediche e Cliniche “L. Sacco”, University of Milan, 20157 Milan, Italy; mara.biasin@unimi.it
- * Correspondence: caruz@ujaen.es; Tel.: +34-95321-2706; Fax: +34-95321-1875



Citation: Serrano-Rísquez, C.; Omar, M.; Gómez-Vidal, M.A.; Real, L.M.; Pineda, J.A.; Rivero, A.; Rivero-Juárez, A.; Forthal, D.; Márquez, F.J.; Lo Caputo, S.; et al. *CD46 Genetic Variability and HIV-1 Infection Susceptibility*. *Cells* **2021**, *10*, 3094. <https://doi.org/10.3390/cells10113094>

Academic Editor: Philippe Gally

Received: 28 September 2021

Accepted: 4 November 2021

Published: 9 November 2021

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: *CD46* is the main receptor for complement protein C3 and plays an important role in adaptive immune responses. *CD46* genetic variants are associated with susceptibility to several infectious and autoimmune diseases. Additionally, *CD46* function can be subverted by HIV-1 to evade attack by complement, a strategy shared by viruses of other families. We sought to determine the association between *CD46* gene variants and HIV-1 acquired through intravenous drug use (IDU) and sexual routes ($n = 823$). Study subjects were of European ancestry and were HIV-1 infected ($n = 438$) or exposed but seronegative ($n = 387$). Genotyping of the rs2796265 SNP located in the *CD46* gene region was done by allele-specific real-time PCR. A meta-analysis merging IDU and sexual cohorts indicates that the minor genotype (CC) was associated with increased resistance to HIV-1 infection OR = 0.2, 95% CI (0.07–0.61), $p = 0.004$. The HIV-1-protective genotype is correlated with reduced *CD46* expression and alterations in the ratio of *CD46* mRNA splicing isoforms.

Keywords: HIV-1; HIV exposed seronegative; HESN; *CD46*; complement

1. Introduction

The complement system is a fundamental part of the innate and adaptive immune system and is required for the elimination of pathogens, immune complexes, and apoptotic cells. After exposure to pathogens, the core complement protein C3 is cleaved to C3b via the classical-lectin or the alternative pathways giving rise to the formation of active C3b convertases that trigger a massive conversion of C3b onto the adjacent pathogen surfaces [1]. The process continues until the formation of the membrane attack complex that destroys microbes through a pore in their membrane. In parallel, proteolysis of C3b to iC3b generates an opsonin that tags microbes for recognition and phagocytosis mediated by complement receptors expressed on phagocytes and lymphocytes [1,2]. This is a highly regulated process to avoid complement-mediated tissue injury. *CD46* (membrane cofactor protein [MCP]) belongs to the family of membrane-bound regulators of complement activation

that inhibit off-target complement deposition and activation on host-cell surfaces [3]. *CD46* acts by preventing the formation of the C4b2a C3 convertase from the classical-lectin pathway or interferes with the conversion of factor B to Bb by factor D, thereby preventing the formation of the C3-convertase of the alternative pathway [1,2]. Other complement regulators are cofactors for complement factor I-mediated proteolysis and inactivation of C4b and C3b. This activity is assisted by a set of other soluble inhibitors of complement activation present in the serum, such as CFH or C4BP.

HIV can directly activate the classical cascade of the complement system, even in the absence of HIV-specific antibodies [4]. After seroconversion, the presence of antibodies further enhances complement deposition on the viral surface [5,6]. Furthermore, mannose-binding lectin, the trigger of the lectin pathway, can activate this branch of the complement system through binding to the HIV envelope [7]. Although high amounts of complement C3b are deposited on HIV viral surface, further complement-mediated lysis of the virus is quite inefficient [8]. The cause is that the virion membrane contains regulators of complement activation as *CD46* [9], that block the complement-dependent virolysis [10]. The use of anti-*CD46* antibodies renders HIV-1 susceptible to complement lysis giving rise to a significant reduction in HIV-1 infectivity [9].

Other viruses also incorporate *CD46* in the virion particles during the budding process, giving the pathogens protection against complement-mediated destruction. Human *CD46* or viral-encoded homologs are packaged as functional complement regulators in the outer membrane of several viral families such as the paramyxoviruses [11,12], rhabdoviruses [13], retroviruses [9,10], herpesviruses, and poxviruses [14].

CD46 shows moonlighting properties [15] with additional and independent functions in several physiological processes including the initial phases of oocyte fertilization [16], neurogenesis, neuronal migration, synaptic remodeling [17]. Furthermore, *CD46* is an alternative receptor for the protein Jagged1 of the Notch signaling pathway [18]. The *CD46*-Jagged1 axis influences T lymphocyte proliferation, survival, and differentiation into a Th1 effector phenotype. Individuals with *CD46* or Jagged1 mutations do not develop Th1 responses and are extremely susceptible to infectious diseases during childhood [18]. *CD46* activation triggers intracellular signaling cascades in macrophages and dendritic cells giving rise to upregulation of pro-inflammatory cytokines such as IL12 or IFN α/β [19–21]. *CD46* also influences the migratory ability and cell-to-cell interaction of T lymphocytes and MHC-II antigen presentation [22]. Recently, a new autocrine *CD46*-mediated signaling has been discovered in T lymphocytes. That is based on the proteolysis of cytoplasmic-stored C3 present in lymphocytes. This proteolysis renders functionally relevant products (C3a and C3b) that are essential for T lymphocyte survival and proliferation [23,24].

CD46 plays a key role in several infectious diseases and has been designated as a “pathogen magnet”. Unrelated microbes use this protein as the cell entry receptor. Several clinically relevant bacterial pathogens have evolved to adopt *CD46* as a receptor or attachment protein, including *Streptococcus pyogenes* [25], *Neisseria meningitidis*, *Neisseria gonorrhoeae* [26], *Escherichia coli* [27], *Klebsiella pneumoniae* [28], and *Fusobacterium nucleatum* [29]. Measles virus [30], human herpesvirus 6 virus [31], cytomegalovirus [32], and adenoviruses of several serotypes [33] also utilize *CD46* as a receptor. The use of this common receptor goes beyond an easily available cell attachment protein. Rather, it is most likely the intracellular signaling cascades induced by *CD46* engagement that provide the pathogens with an advantage in the host, either by facilitating the rupture of protective host barriers or by creating a more permissive immune environment [34].

A puzzling observation is the alteration of the *CD46* mRNA splicing in HIV-1 infected cells, giving rise to a protein lacking an extracellular glycosylation domain [35]. The functional significance of this finding is not established, neither the differential physiological tasks of the *CD46* isoforms [35]. Additionally, significantly lower expression of *CD46* on the surface of dendritic cells [36], lung alveolar CD4+ lymphocytes [37], and peripheral blood mononuclear cells [38] of HIV-1 infected individuals compared to healthy donors

were found, suggesting that modulation of *CD46* expression may influence HIV-1 infection and disease progression [36].

HIV-1 exposed seronegative (HESN) individuals are a heterogeneous group who remain HIV-1 uninfected despite exposure to the virus (intravenous drug and chemsex users, serodiscordant couples, men who have sex with men, and children born to HIV-1 infected mothers). Why infection after exposure appears to be resisted by some is likely due to multiple factors [39]. A better understanding of these factors may lead to novel prevention strategies, the discovery of antiviral targets, and the development of new vaccination strategies. In a previous study, using hypothesis-driven candidate gene strategies, we tested several hundred polymorphisms of complement-related genes and found one SNP located at the CR2 gene that was associated with HESN status in intravenous drug users (IDU) [40]. This finding was replicated in an independent population at risk of infection through sexual exposure. CR2 was later associated with the rate of infection after HIV-1 vaccination with rgp120 protein [41]. One SNP in the *CD46* gene was initially discarded due to a non-significant association with HIV-1 status after adjustment for multiple testing. This SNP showed a strong deviation from Hardy–Weinberg equilibrium. However, after a detailed analysis of the data, we found that the origin of this deviation was restricted to the HIV-1-infected individuals with one of the homozygous genotypes virtually absent in this population, suggesting a protective role during infection. In this current work, we have tested the potential role of this SNP as an HIV-1 resistance factor in independent populations (from Spain, Italy, and the USA) at risk of infection through sexual routes and performed a meta-analysis with the previous data obtained from IDU cohorts.

2. Materials and Methods

2.1. Study Population

We analyzed 823 individuals exposed to HIV-1 by the intravenous ($n = 441$) and sexual routes ($n = 382$) from Spain, Italy, and the United States. Among them, 438 HIV-1 were seropositive and 387 were considered as HESN. This group includes intravenous drug users, heterosexual discordant couples who routinely had unprotected sexual intercourse, and men who have sex with men (MSM). The MSM group includes Spanish individuals with high-risk behavior (chemsex) and placebo recipients participating in the Vax004 trial (Clinical-Trials.gov Identifier: NCT00002441) [42]. Samples are from available volunteers that became infected with HIV during the trial and a random sample of volunteers that remained uninfected. The main epidemiological and clinical characteristics of these volunteers have been previously described [41–43]. The present study included uninfected volunteers classified as having a high baseline risk of infection based on self-reported behaviors during the 6 months before enrollment. These behaviors were highly predictive of HIV infection in men [42]. Behavioral risk scores were calculated on the basis of the number of risk factors reported: unprotected receptive anal sex with an HIV-1-infected male partner; unprotected insertive anal sex with an HIV-1-infected male partner; unprotected receptive anal sex with an HIV-1-uninfected male partner; five or less acts of unprotected receptive anal sex with a male partner of unknown HIV-1 status; 10 or less sex partners; anal herpes; hepatitis A; use of poppers; and use of amphetamines. The inclusion criteria and main characteristics of these patients have been previously described in detail elsewhere [41–43].

2.2. Genotyping

DNA was extracted from frozen whole blood samples or saliva using the Quick Pure Blood DNA extraction kit. The *CD46* polymorphism was genotyped by allele-specific real-time PCR using the Biorad CFX equipment (Bio-Rad Laboratories Inc., Hercules, CA, USA).

2.3. Biostatistics and Bioinformatics Analysis

Hardy–Weinberg equilibrium and genetic associations were assessed using the online tool (available online at <https://ihg.gsf.de/cgi-bin/hw/hwa1.pl> (accessed on 13 June 2021))

and the PLINK software (<http://zzz.bwh.harvard.edu/plink/> (accessed on 12 June 2021)). Results from the sexual cohorts were combined with results from the IDU cohort using a fixed-effect meta-analysis. This meta-analysis was estimated with the online tool MetaGenyo developed at the “Centro Pfizer–Universidad de Granada–Junta de Andalucía de Genómica e Investigación Oncológica” (<https://metagenyo.genyo.es/> (accessed on 13 June 2021)). This tool was also used for odds ratios (ORs) representation in Forest plots.

Levels of mRNA expression according to *CD46* rs2796265 genotypes were calculated using the GTEx portal (<https://gtexportal.org/home/snp/rs2796265> (accessed on 19 June 2021)) Analysis Release V8 (dbGaP Accession phs000424.v8.p2) [13]. This portal allows testing of associations between SNPs and expression quantitative trait loci (eQTL) and splicing quantitative trait loci (sQTL) [44].

2.4. Ethics

This study was designed and performed according to the principles of the Helsinki Declaration and was approved by the Institutional Review Board of the Province of Jaen, Junta de Andalucía (GEN-VIH/0646-N-20 version 1 of 09/03/2020 and Protocol “Identificación de factores genéticos de Resistencia innata a la infección por VIH-1” of 26/07/2018). The participating centers and hospitals were: Complejo Hospitalario de Jaén (Jaén), Hospital Universitario Reina Sofía (Cordoba), S. Maria Annunziata Hospital (Florence) and Global Solutions for Infectious Diseases (San Francisco). All patients and healthy blood donors provided written informed consent to participate in this study.

3. Results

Sociodemographic and clinical variables of the subjects were previously described [45–51]. Two individuals in the HESN group were homozygous for CCR5 Δ 32 and were excluded from subsequent analysis. Nine SNPs located in the CD46 locus were genotyped previously [40], and none of them, except rs2796265, showed a nominally significant association with HIV-1 status ($p = 10^{-3}$) (Supplementary Table S1).

A strong deviation from Hardy–Weinberg equilibrium was observed for rs2796265 in IDU HIV-1 positive ($p = 0.005$) and sexual groups ($p = 0.03$). No departure from Hardy–Weinberg equilibrium was observed in the IDU ($p = 0.3$) or sexual ($p = 0.4$) HESN cohorts (Table 1).

Table 1. Allelic and genotypic distribution in HIV-1 infected and HESN subjects.

IDU	Cohorts	Alleles ^a		Genotypes ^a	
		C	C/C	C/T	T/T
	HIV-1, n (%) $p^c = 0.005$	83 (17.2)	1 (0.004)	81 (34)	159 (66)
	HESN, n (%) * $p^c = 0.3$	83 (20.7)	11 (6.0)	65 (31)	118 (64)
	Association test ^b	C vs. T	C/C vs. T/T	C/C vs. C/T	C/C vs. C/T + T/T
	OR (95% CI)	0.83 (0.58–1.2)	0.07 (0.009–0.5)	0.06 (0.008–0.5)	0.07 (0.009–0.5)
	p -value ^b	0.18	0.001	0.001	0.001
Sex	Cohorts	Alleles ^a		Genotypes ^a	
		C	C/C	C/T	T/T
	HIV-1, n (%) $p^c = 0.031$	71 (18)	3 (1.5)	65 (33.1)	128 (65.3)
	HESN, n (%) $p^c = 0.4$	80 (22)	9 (4.8)	62 (3.3)	108 (61)
	Association test ^b	C vs. T	C/C vs. T/T	C/C vs. C/T	C/C vs. C/T + T/T
	OR (95% CI)	0.81 (0.5–1.2)	0.32 (0.08–1.2)	0.3 (0.07–1.2)	0.31 (0.08–1.2)
	p -value ^b	0.23	0.08	0.06	0.06

Table 1. Cont.

IDU + Sex	Cohorts	Alleles ^a		Genotypes ^a	
		C	C/C	C/T	T/T
	HIV-1, n (%) $p^c = p = 0.001$	154 (17.8)	4 (0.01)	146 (33)	287 (65)
	HESN, n (%) $p^c = 0.3$	163 (20.8)	20 (5.1)	123 (31)	243 (62)
	Association test ^b	C vs. T	C/C vs. T/T	C/C vs. C/T	C/C vs. C/T + T/T
	OR (95% CI)	0.8 (0.6–1.0)	0.13 (0.03–0.04)	0.13 (0.03–0.04)	0.13 (0.03–0.04)
	p -value ^b	0.07	0.0004	0.0003	0.0002

Notes: ^a Data are allele or genotype counts (%). ^b Fisher's exact test. OR: Odds Ratio. CI: Confidence interval. ^c Test for deviation of Hardy–Weinberg equilibrium. * Individuals homozygous for CCR5Δ32 and were excluded from this analysis.

The comparison of genotype frequencies revealed a remarkably differential distribution of the CD46 rs2796265 genotypes in HIV-1 positive patients compared to HESN subjects (Table 1). Thus, the frequency of homozygous individuals with the minor allele (CC) was significantly higher in IDU HESN subjects compared to IDU HIV-1 positive subjects (6% vs. 0.004%, $p = 0.001$). Minor allele homozygotes (CC vs. CT + TT) appear as a resistance factor for HIV-1 infection (OR = 0.07; $p = 0.001$; Table 1). A similar trend (although not statistically significant) was found when comparing the sexually exposed HESN with HIV-1 positive subjects (OR = 0.3; $p = 0.06$; Table 1). Combining all samples confirms the association with a lower risk of infection for the minor allele under a recessive model C/C vs. C/T + T/T; OR = 0.13, $p = 0.0001$ (Table 1).

The results of the two populations at risk of parenteral and sexual HIV-1 transmission were combined through a fixed-effect meta-analysis and yielded a significant difference for the comparison including the genotypes CC vs. CT + TT (OR = 0.2; $p = 0.0045$; heterogeneity test $p = 0.24$). The evaluation of the CC vs. TT genotypes yielded a similar OR (0.19; $p = 0.0044$; heterogeneity $p = 0.26$; Figure 1), compatible with a recessive mode of expression of this protective factor concerning HIV-1 susceptibility.




Figure 1. Forrest plot of meta-analysis of the sexual and IDU populations: OR and 95% Confidence interval and fixed-effect meta-analysis. $p = 0.0044$ for a recessive model of the protective allele (<https://metagenyo.genyo.es/> (accessed on 13 June 2021)).

The role of the rs2796265 polymorphism in the expression of the CD46 gene was investigated through the GTEx portal (ReleaseV7; <https://www.gtexportal.org> (accessed on 19 June 2021)). CD46 mRNA is ubiquitously expressed in human tissues (Figure 2).

When expression-quantitative trait locus (eQTL) analysis was performed, we observed that the HIV-1 protective C allele correlated with lower CD46 expression across several tissues (Figure 3). CD46 expression in homozygotes C/C subjects is significantly decreased: oesophagus ($p = 5.9 \times 10^{-53}$), brain ($p = 1.7 \times 10^{-36}$), spleen ($p = 3.1 \times 10^{-7}$), and immortalized B-lymphocytes ($p = 1.0 \times 10^{-6}$).




Figure 2. CD46 expression in different tissues (GTEx portal). TMP: Transcripts per million reads.




Figure 3. Illustrative violin plot where CD46 normalized expression is plotted according to the rs2796265 genotypes determined in cultured fibroblasts, spleen, brain, and immortalized B-lymphocytes according to GTEx portal. Protective genotype CC show significant lower levels of expression in several representative tissues: Esophagus ($p = 5.9 \times 10^{-53}$), brain ($p = 1.7 \times 10^{-36}$), spleen ($p = 3.1 \times 10^{-7}$), immortalized B-lymphocytes ($p = 1.0 \times 10^{-6}$). The values between parentheses represent the number of samples included in each genotype.

Furthermore, rs2796265 genotypes correlate with a highly significant CD46 mRNA splicing quantitative locus in several tissues: fibroblast ($p = 1.4 \times 10^{-259}$), oesophagus ($p = 1.7 \times 10^{-188}$), immortalized B-lymphocytes ($p = 2.1 \times 10^{-57}$), or brain-cortex ($p = 1.3 \times 10^{-25}$) (Figure 4).




Figure 4. Relationship between the rs2796265 SNP genotypes and the normalized intron-excision ratio in four representative tissues: Fibroblast ($p = 1.4 \times 10^{-259}$), esophagus ($p = 1.7 \times 10^{-188}$), immortalized B-lymphocytes ($p = 2.1 \times 10^{-57}$), brain-cortex ($p = 1.3 \times 10^{-25}$). The splicing phenotype IDs are constructed by LeafCutter, and indicate the intron (chr:start:end) and cluster of connected components (clu_) the intron belongs to [44].

4. Discussion

The function of CD46 in innate and adaptive immune responses is a matter of considerable interest as restriction of CD46-mediated signaling pathways is associated with innate immunodeficiency. Individuals with sporadic severe mutations in *CD46* cannot generate a Th1 response and develop recurrent severe infections [18]. In parallel, patients with mutations in Jagged-1, a CD46 ligand, suffer from Alagille Syndrome and recurrent viral infections due to deficient protective Th1 immunity [18]. Common *CD46* polymorphisms are also associated with immune-related phenotypes such as febrile seizures following virus vaccination [52], neutralizing antibody responses to measles vaccine [53], and blood monocyte counts [54]. Other unrelated phenotypes such as atypical hemolytic uremic syndrome, heart rate response to exercise and recovery, and blood pressure, preeclampsia, spontaneous pregnancy loss, systemic sclerosis, glomerulonephritis, and thrombotic throm-

bocytopenic purpura have been also associated with *CD46* gene variation [14], highlighting the pleiotropic function of this protein.

Our finding that the minor allele of rs2796265 is significantly underrepresented in HIV-1 infected individuals supports a role for *CD46* in the HESN phenotype. Moreover, the association with HIV-1 susceptibility represents a new phenotype related to the *CD46* gene. Although the finding does not reach statistical significance in individuals at risk through the sexual route, we observe the same trend as found in IDU. The smaller number of subjects in the sex HESN group may explain the lack of significant results in this population. The sexually exposed non-infected individuals have an a priori lower risk of HIV-1 compared to exposed intravenous drug users and some sex HESN could be misclassified.

The SNP rs2796265 is located in the promoter region of *CD46*, and the alleles are correlated to mRNA levels and splicing isoforms ratio supporting a role in the pathogenesis of HIV-1 infection, as previously suggested [10]. It is plausible that lower complement inhibitory activity of the isoforms expressed by the minor allele may lead the virus more susceptible to complement attack. Alternatively, the explanation for the association here reported may be related to the complex immune regulatory networks depending on *CD46* signaling as Th1 response. The SNP rs2796265 belongs to a linkage disequilibrium block that includes several intronic SNPs. All of the minor alleles of this block (containing the HIV-resistance allele) have been found to influence at least two phenotypes. Minor allele homozygotes of rs2796265 showed about half the median neutralizing antibody titer against measles virus after vaccination compared with the major allele [53]. Paradoxically, the same individuals produce more IFN α in PBMC cultures after in vitro stimulation [53]. The correlation between the protective genotype and higher IFN α production in response to viral infection [53] could be an alternative explanation to the association here reported.

Four main *CD46* isoforms are resulting from alternative splicing in most human tissues. The extracellular portion of *CD46* consists of four conserved short consensus repeats, an O-glycosylated area enriched in serines, threonines, and prolines (STP domain), a transmembrane segment, and a cytoplasmic tail (16 or 23 amino acids depending on differential splicing). *CD46* exon 7 and 8 are mutually exclusive [35], RNAseq data from previous studies [53] and those obtained by us, confirm that the haplotype carrying the SNP rs2796265 influences exon skipping and total *CD46* mRNA expression. Remarkably, exon 7 was found to be skipped in HIV-1 infected T cells, generating an alternative protein product lacking the extracellular STP region [35]. Moreover, lymphocytes and dendritic cells from HIV-1 infected patients show significant lower levels of extracellular *CD46* expression, indicative that *CD46* may influence the pathophysiology of the HIV-1 infection [9,35,36,38]. Future studies have to address the functional relevance of *CD46* genomic variation and its relationship with mRNA, protein expression, and its regulation by cytokines under the context of HIV-1 susceptibility and disease progression.

The main limitation of our research is the small population included in the meta-analysis and the possible bias due to the number of minor homozygotes, small random deviations can have consequences in the statistical significance.

5. Conclusions

Our results suggest that *CD46* has a role in innate resistance to HIV-1 infection, which supports the importance of complement receptors and regulators in the pathogenesis of HIV infection. Further research and replication are needed to confirm this data and to explain how genetic variation in *CD46* influences innate immunity against HIV-1. If our results are confirmed, they may lead to a new potential target for pharmacological intervention in HIV-1 infection by modulation of *CD46* signaling.

6. Patents

No patent pending related to this study.

Supplementary Materials: The following are available online at <https://www.mdpi.com/article/10.3390/cells10113094/s1>, Table S1: Association of SNP in *CD46* locus with HIV-1 resistance in IDU.

Author Contributions: All authors substantially contributed to this work. Conceptualization, A.C., C.S.-R. and L.M.R.; methodology, A.C., L.M.R., D.F., M.B., M.C., S.L.C., F.J.M. and D.F.; software, A.C.; formal analysis, A.C. and C.S.-R.; re-sources, M.O., M.A.G.-V., L.M.R., J.A.P., A.R., A.R.-J., D.F., S.L.C., M.C. and M.B.; writing—original draft preparation, A.C. and C.S.-R.; writing—review and editing, all the authors.; supervision, A.C.; project administration, A.C.; funding acquisition, A.C. and F.J.M. All authors have read and agreed to the published version of the manuscript.

Funding: FunThis research was funded by grant SAF2016-80125-R (Ministerio de Economía, Industria y Competitividad, Spain) to A. Caruz and F. J. Marquez and grant 1381073-2020 from European Regional Development Fund to Antonio Caruz.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of the Province of Jaen, Junta de Andalucía (GEN-VIH/0646-N-20 version 1 of 09/03/2020 and Protocol “Identificación de factores genéticos de Resistencia innata a la infección por VIH-1” of 26 July 2018).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data generated during the current study are available from the corresponding author on reasonable request.

Acknowledgments: The authors thank the staff members of Global Solutions for Infectious Diseases, the Division of AIDS (National Institute of Allergy and Infectious Diseases, National Institutes of Health) as well as the company Precision for Medicine for assistance in the selection and management of the samples; we are greatly indebted to Faruk Sinangil and Keith Higgins (GSID), Jon Warren (DAIDS) and Karen Carter (PFM).

Conflicts of Interest: The authors declare no conflict of interest.

References

- Merle, N.S.; Church, S.E.; Fremeaux-Bacchi, V.; Roumenina, L.T. Complement system part I—Molecular mechanisms of activation and regulation. *Front. Immunol.* **2015**, *6*, 262. [[CrossRef](#)] [[PubMed](#)]
- Merle, N.S.; Noe, R.; Halbwachs-Mecarelli, L.; Fremeaux-Bacchi, V.; Roumenina, L.T. Complement system part II: Role in immunity. *Front. Immunol.* **2015**, *6*, 257. [[CrossRef](#)] [[PubMed](#)]
- Yamamoto, H.; Fara, A.; Dasgupta, P.; Kemper, C. CD46: The ‘multitasker’ of complement proteins. *Int. J. Biochem. Cell Biol.* **2013**, *45*, 2808–2820. [[CrossRef](#)] [[PubMed](#)]
- Stoiber, H.; Clivio, A.; Dierich, M.P. Role of complement in HIV infection. *Annu. Rev. Immunol.* **1997**, *15*, 649–674. [[CrossRef](#)]
- Bánki, Z.; Stoiber, H.; Dierich, M.P. HIV and human complement: Inefficient virolysis and effective adherence. *Immunol. Lett.* **2005**, *97*, 209–214. [[CrossRef](#)]
- Prohászka, Z.; Hidvégi, T.; Ujhelyi, E.; Stoiber, H.; Dierich, M.P.; Süsal, C.; Füst, G. Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1. *Immunology* **1995**, *85*, 184–189.
- Ji, X.; Gewurz, H.; Spear, G.T. Mannose binding lectin (MBL) and HIV. *Mol. Immunol.* **2005**, *42*, 145–152. [[CrossRef](#)]
- Stoiber, H.; Kacani, L.; Speth, C.; Würzner, R.; Dierich, M.P. The supportive role of complement in HIV pathogenesis. *Immunol. Rev.* **2001**, *180*, 168–176. [[CrossRef](#)]
- Montefiori, D.C.; Cornell, R.J.; Zhou, J.Y.; Zhou, J.T.; Hirsch, V.M.; Johnson, P.R. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. *Virology* **1994**, *205*, 82–92. [[CrossRef](#)]
- Saifuddin, M.; Hedayati, T.; Atkinson, J.; Holguin, M.; Parker, C.; Spear, G. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. *J. Gen. Virol.* **1997**, *78*, 1907–1911. [[CrossRef](#)]
- Biswas, M.; Johnson, J.B.; Kumar, S.R.P.; Parks, G.D.; Subbiah, E. Incorporation of host complement regulatory proteins into newcastle disease virus enhances complement evasion. *J. Virol.* **2012**, *86*, 12708–12716. [[CrossRef](#)]
- Li, Y.; Parks, G.D. Relative contribution of cellular complement inhibitors CD59, CD46, and CD55 to parainfluenza virus 5 inhibition of complement-mediated neutralization. *Viruses* **2018**, *10*, 219. [[CrossRef](#)]
- Ozog, S.; Chen, C.X.; Simpson, E.; Garijo, O.; Timberlake, N.D.; Minder, P.; Verhoeyen, E.; Torbett, B.E. CD46 null packaging cell line improves measles lentiviral vector production and gene delivery to hematopoietic stem and progenitor cells. *Mol. Ther. Methods Clin. Dev.* **2019**, *13*, 27–39. [[CrossRef](#)]
- Kathryn Liszewski, M.; Atkinson, J.P. Complement regulator CD46: Genetic variants and disease associations. *Hum. Genom.* **2015**, *9*, 1–13. [[CrossRef](#)]
- Turek, I.; Irving, H. Moonlighting proteins shine new light on molecular signaling niches. *Int. J. Mol. Sci.* **2021**, *22*, 1367. [[CrossRef](#)]
- Anderson, D.; Abbott, A.; Jack, R. The role of complement component C3b and its receptors in sperm-oocyte interaction. *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 10051–10055. [[CrossRef](#)]

17. Díaz-Morán, S.; Palència, M.; Mont-Cardona, C.; Cañete, T.; Blázquez, G.; Martínez-Membrives, E.; López-Aumatell, R.; Sabariego, M.; Donaire, R.; Morón, I.; et al. Gene expression in hippocampus as a function of differential trait anxiety levels in genetically heterogeneous NIH-HS rats. *Behav. Brain Res.* **2013**, *257*, 129–139. [[CrossRef](#)]
18. Le Friec, G.; Sheppard, D.; Whiteman, P.; Karsten, C.; Shamoun, S.; Laing, A.; Bugeon, L.; Dallman, M.; Melchionna, T.; Chillakuri, C.; et al. The CD46-Jagged1 interaction is critical for human TH1 immunity. *Nat. Immunol.* **2012**, *13*, 1213–1221. [[CrossRef](#)]
19. Sakurai, F.; Nakashima, K.; Yamaguchi, T.; Ichinose, T.; Kawabata, K.; Hayakawa, T.; Mizuguchi, H. Adenovirus serotype 35 vector-induced innate immune responses in dendritic cells derived from wild-type and human CD46-transgenic mice: Comparison with a fiber-substituted Ad vector containing fiber proteins of Ad serotype 35. *J. Control. Release* **2010**, *148*, 212–218. [[CrossRef](#)]
20. Hirano, A.; Kurita-Taniguchi, M.; Katayama, Y.; Matsumoto, M.; Wong, T.; Seya, T. Ligation of human CD46 with purified complement C3b or F(ab')₂ of monoclonal antibodies enhances isoform-specific interferon gamma-dependent nitric oxide production in macrophages. *J. Biochem.* **2002**, *132*, 83–91. [[CrossRef](#)]
21. Kurita-Taniguchi, M.; Fukui, A.; Hazeki, K.; Hirano, A.; Tsuji, S.; Matsumoto, M.; Watanabe, M.; Ueda, S.; Seya, T. Functional modulation of human macrophages through CD46 (measles virus receptor): Production of IL-12 p40 and nitric oxide in association with recruitment of protein-tyrosine phosphatase SHP-1 to CD46. *J. Immunol.* **2000**, *165*, 5143–5152. [[CrossRef](#)]
22. Oliaro, J.; Pasam, A.; Waterhouse, N.J.; Browne, K.; Ludford-Menting, M.; Trapani, J.; Russell, S. Ligation of the cell surface receptor, CD46, alters T cell polarity and response to antigen presentation. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 18685–18690. [[CrossRef](#)]
23. Liszewski, M.K.; Kolev, M.; Le Friec, G.; Leung, M.; Bertram, P.G.; Fara, A.F.; Subias, M.; Pickering, M.C.; Drouet, C.; Meri, S.; et al. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. *Immunity* **2013**, *39*, 1143–1157. [[CrossRef](#)]
24. Arbore, G.; West, E.E.; Rahman, J.; Le Friec, G.; Niyonzima, N.; Pirooznia, M.; Tunc, I.; Pavlidis, P.; Powell, N.; Li, Y.; et al. Complement receptor CD46 co-stimulates optimal human CD8+ T cell effector function via fatty acid metabolism. *Nat. Commun.* **2018**, *9*, 1–15. [[CrossRef](#)]
25. Oliver, M.A.; Rojo, J.M.; Rodriguez de Cordoba, S.; Alberti, S. Binding of complement regulatory proteins to group A Streptococcus. *Vaccine* **2008**, *26*, 175–178. [[CrossRef](#)]
26. Gill, D.B.; Koomey, M.; Cannon, J.G.; Atkinson, J.P. Down-regulation of CD46 by Piliated Neisseria gonorrhoeae. *J. Exp. Med.* **2003**, *198*, 1313–1322. [[CrossRef](#)]
27. Li, K.; Feito, M.; Sacks, S.; Sheerin, N. CD46 (membrane cofactor protein) acts as a human epithelial cell receptor for internalization of opsonized uropathogenic Escherichia coli. *J. Immunol.* **2006**, *177*, 2543–2551. [[CrossRef](#)]
28. de Astorza, B.; Cortés, G.; Crespi, C.; Saus, C.; Rojo, J.; Alberti, S. C3 promotes clearance of Klebsiella pneumoniae by A549 epithelial cells. *Infect. Immun.* **2004**, *72*, 1767–1774. [[CrossRef](#)]
29. Mahtout, H.; Chandad, F.; Rojo, J.M.; Grenier, D. Fusobacterium nucleatum Binding to complement regulatory protein CD46 modulates the expression and secretion of cytokines and matrix metalloproteinases by oral epithelial cells. *J. Periodontol.* **2011**, *82*, 311–319. [[CrossRef](#)]
30. Dörig, R.; Marcil, A.; Chopra, A.; Richardson, C. The human CD46 molecule is a receptor for measles virus (Edmonston strain). *Cell* **1993**, *75*, 295–305. [[CrossRef](#)]
31. Santoro, F.; Kennedy, P.E.; Locatelli, G.; Malnati, M.S.; Berger, E.A.; Lusso, P. CD46 is a cellular receptor for human herpesvirus 6. *Cell* **1999**, *99*, 817–827. [[CrossRef](#)]
32. Stein, K.R.; Gardner, T.J.; Hernandez, R.E.; Kraus, T.A.; Duty, J.A.; Ubarretxena-Belandia, I.; Moran, T.M.; Tortorella, D. CD46 facilitates entry and dissemination of human cytomegalovirus. *Nat. Commun.* **2019**, *10*, 1–13. [[CrossRef](#)] [[PubMed](#)]
33. Chen, R.F.; Lee, C.Y. Adenoviruses types, cell receptors and local innate cytokines in adenovirus infection. *Int. Rev. Immunol.* **2014**, *33*, 45–53. [[CrossRef](#)] [[PubMed](#)]
34. Liszewski, M.K.; Atkinson, J.P. Membrane cofactor protein (MCP; CD46): Deficiency states and pathogen connections. *Curr. Opin. Immunol.* **2021**, *72*, 126–134. [[CrossRef](#)] [[PubMed](#)]
35. Byun, S.; Han, S.; Zheng, Y.; Planelles, V.; Lee, Y. The landscape of alternative splicing in HIV-1 infected CD4 T-cells. *BMC Med. Genom.* **2020**, *13*, 38. [[CrossRef](#)] [[PubMed](#)]
36. Mishra, N.; Mohata, M.; Aggarwal, H.; Chaudhary, O.; Das, B.K.; Sinha, S.; Hazarika, A.; Luthra, K. Expression of complement receptor 3 (CR3) and regulatory protein CD46 on dendritic cells of antiretroviral naïve and treated HIV-1 infected individuals: Correlation with immune activation status. *Mol. Immunol.* **2018**, *96*, 83–87. [[CrossRef](#)] [[PubMed](#)]
37. Aries, S.P.; Schaaf, B.; Hansen, F.; Weyrich, K.; Kurowski, V.; Dennin, R.; Dalhoff, K. Expression of complement receptors and regulatory proteins on alveolar CD4+ lymphocytes from human immunodeficiency virus-1 infected individuals. *Eur. Respir. J.* **1997**, *10*, 1736–1741. [[CrossRef](#)] [[PubMed](#)]
38. Jarvis, J.N.; Taylor, H.; Long, P.M.; Gutta, P.V.; Pousak, T.; Fine, N. Diminished expression of cell-surface complement regulatory proteins in HIV-infected children and with HIV infection of peripheral blood mononuclear cells in vitro. *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.* **1995**, *9*, 249–256. [[CrossRef](#)]
39. Fenizia, C.; Rossignol, J.-F.; Clerici, M.; Biasin, M. Genetic and immune determinants of immune activation in HIV-exposed seronegative individuals and their role in protection against HIV infection. *Infect. Genet. Evol.* **2018**, *66*, 325–334. [[CrossRef](#)]

40. Herrero, R.; Real, L.M.; Rivero-Juárez, A.; Pineda, J.A.; Camacho, Á.; Macías, J.; Laplana, M.; Konieczny, P.; Márquez, F.J.; Souto, J.C.; et al. Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection. *Genes Immun.* **2015**, *16*, 134–141. [[CrossRef](#)]
41. Meza, G.; Expósito, A.; Royo, J.L.; Ruiz-García, C.; Sánchez-Arcas, B.; Marquez, F.J.; Gómez-Vidal, M.A.; Omar, M.; Sinangil, F.; Higgins, K.; et al. Association of Complement C3d receptor 2 genotypes with the acquisition of HIV infection in a trial of recombinant glycoprotein 120 Vaccine. *AIDS* **2020**, *34*, 25–32. [[CrossRef](#)]
42. Flynn, N.M.; Forthal, D.N.; Harro, C.D.; Judson, F.N.; Mayer, K.H.; Para, M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. *J. Infect. Dis.* **2005**, *191*, 654–665. [[CrossRef](#)]
43. Gilbert, P.B.; Peterson, M.L.; Follmann, D.; Hudgens, M.G.; Francis, D.P.; Gurwith, M.; Heyward, W.L.; Jobes, D.V.; Popovic, V.; Self, S.G.; et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. *J. Infect. Dis.* **2005**, *191*, 666–677. [[CrossRef](#)]
44. Li, Y.; Knowles, D.; Humphrey, J.; Barbeira, A.; Dickinson, S.; Im, H.; Pritchard, J. Annotation-free quantification of RNA splicing using LeafCutter. *Nat. Genet.* **2018**, *50*, 151–158. [[CrossRef](#)]
45. Sironi, M.; Biasin, M.; Gnudi, F.; Cagliani, R.; Saulle, I.; Forni, D.; Rainone, V.; Trabattoni, D.; Garziano, M.; Mazzotta, F.; et al. A regulatory polymorphism in HAVCR2 modulates susceptibility to HIV-1 infection. *PLoS ONE* **2014**, *9*, e106442. [[CrossRef](#)]
46. Rallon, N.I.; Restrepo, C.; Naggie, S.; Lopez, M.; del Romero, J.; Goldstein, D.; McHutchison, J.; Soriano, V.; Benito, J.M. Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. *AIDS* **2011**, *25*, 269–271. [[CrossRef](#)]
47. Biasin, M.; Sironi, M.; Saulle, I.; de Luca, M.; la Rosa, F.; Cagliani, R.; Forni, D.; Agliardi, C.; lo Caputo, S.; Mazzotta, F.; et al. Endoplasmic reticulum aminopeptidase 2 haplotypes play a role in modulating susceptibility to HIV infection. *AIDS* **2013**, *27*, 1697–1706. [[CrossRef](#)]
48. Sironi, M.; Biasin, M.; Cagliani, R.; Gnudi, F.; Saulle, I.; Ibba, S.; Filippi, G.; Yahyaei, S.; Tresoldi, C.; Riva, S.; et al. Evolutionary analysis identifies an MX2 haplotype associated with natural resistance to HIV-1 infection. *Mol. Biol. Evol.* **2014**, *31*, 2402–2414. [[CrossRef](#)]
49. Sironi, M.; Biasin, M.; Cagliani, R.; Forni, D.; De Luca, M.; Saulle, I.; Lo Caputo, S.; Mazzotta, F.; Macías, J.; Pineda, J.A.; et al. A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. *J. Immunol.* **2012**, *188*, 818–823. [[CrossRef](#)]
50. Herrero, R.; Pineda, J.A.; Rivero-Juarez, A.; Echbarthi, M.; Real, L.M.; Camacho, A.; Macias, J.; Fibla, J.; Rivero, A.; Caruz, A. Common haplotypes in CD209 promoter and susceptibility to HIV-1 infection intravenous drug users. *Infect. Genet. Evol.* **2016**, *45*, 20–25. [[CrossRef](#)]
51. Jaimes-Bernal, C.; Rallón, N.; Benito, J.M.; Omar, M.; Gómez-Vidal, M.A.; Márquez, F.J.; Sánchez-Arcas, B.; Trujillo, M.; Royo, J.L.; Saulle, I.; et al. A knockout IFNL4 variant is associated with protection from sexually transmitted HIV-1 infection. *J. Infect. Dis.* **2018**, *219*, 772–776. [[CrossRef](#)]
52. Feenstra, B.; Pasternak, B.; Geller, F.; Carstensen, L.; Wang, T.; Huang, F.; Eitson, J.L.; Hollegaard, M.V.; Svanström, H.; Vestergaard, M.; et al. Common variants associated with general and MMR vaccine-related febrile seizures. *Nat. Genet.* **2014**, *46*, 1274–1282. [[CrossRef](#)]
53. Haralambieva, I.; Ovsyannikova, I.; Kennedy, R.; Larrabee, B.; Zimmermann, M.T.; Grill, D.; Schaid, D.; Poland, G. Genome-wide associations of CD46 and IFI44L genetic variants with neutralizing antibody response to measles vaccine. *Hum. Genet.* **2017**, *136*, 421–435. [[CrossRef](#)]
54. Chen, M.; Raffield, L.; Mousas, A.; Sakaue, S.; Huffman, J.; Moscati, A.; Trivedi, B.; Jiang, T.; Akbari, P.; Vuckovic, D.; et al. Trans-ethnic and ancestry-specific blood-cell genetics in 746,667 individuals from 5 global populations. *Cell* **2020**, *182*, 1198–1213. [[CrossRef](#)]